Bronchoscopic Lung Volume Reduction in COPD: Current Evidence and Future Directions

Joseph Bahgat, MD ¹; Antarpreet Kaur, MBBS, FCCP ¹²; Anil Magge, MD ¹²

1. University of Connecticut Health Center, Farmington CT
2. Department of Pulmonary, Critical care and Sleep medicine, Trinity Health of New England, Hartford CT

OPEN ACCESS

PUBLISHED: 31 October 2024

CITATION: Bahgat, J., Kaur, A., et al., 2024. Bronchoscopic Lung Volume Reduction in COPD: Current Evidence and Future Directions. Medical Research Archives, [online] 12(10). https://doi.org/10.18103/mra.v12i10.5764

COPYRIGHT © 2024 European Society of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI https://doi.org/10.18103/mra.v12i10.5764

ISSN 2375-1924

ABSTRACT

Bronchoscopic lung volume reduction has emerged as a promising intervention for patients with chronic obstructive pulmonary disease who remain symptomatic despite optimal medical management. This literature review evaluates the efficacy, safety, and patient selection criteria for bronchoscopic lung volume reduction, focusing on its role in improving lung function, exercise capacity, and quality of life. Techniques such as endobronchial valves, coils, and bronchoscopic thermal vapor ablation offer less invasive alternatives to surgical lung volume reduction by targeting diseased lung regions to reduce hyperinflation. Key clinical trials, including VENT, LIBERATE, and EMPROVE, indicate that bronchoscopic lung volume reduction can provide significant benefits for carefully selected patients, particularly those with heterogeneous emphysema and low collateral ventilation. The VENT trial demonstrated notable improvements in lung function and quality of life, while the LIBERATE trial highlighted the efficacy of endobronchial valves in reducing lung volume and improving exercise capacity. However, the procedure is associated with risks, including pneumothorax, exacerbations, and respiratory infections. Optimal patient selection is crucial, with the greatest benefits observed in patients with upper-lobe predominant emphysema and significant hyperinflation. Pre-procedural evaluation includes high-resolution computed tomography and functional imaging to assess emphysema distribution, identify target lobes, and detect the presence of collateral ventilation. Despite the advantages, long-term efficacy and safety profile require further investigation through larger and more diverse patient populations. This review addresses the clinical implications, emphasizing a multidisciplinary approach to patient selection and management. Future research should focus on refining patient selection criteria, improving procedural techniques, and assessing long-term outcomes to establish standardized protocols and confirm the sustained benefits of bronchoscopic lung volume reduction. Additionally, completing fissures with thoracoscopic surgery to broaden the applicability of bronchoscopic lung volume reduction is an emerging area of research.

Keywords

COPD, bronchoscopic lung volume reduction, endobronchial valves, coils, thermal vapor ablation, emphysema

Introduction:

Chronic obstructive pulmonary disease (COPD) is a chronic and progressive condition affecting an estimated 14 million people in the United States and over 480 million people worldwide, with a higher prevalence in older adults and smokers. The disease is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, typically caused by significant exposure to noxious particles or gases, most commonly from smoking. Without effective treatment, COPD leads to progressive lung function decline, increased morbidity, and mortality.

Hyperinflation of the lungs can occur due to morphological changes in the lung structure of these patients. This physiological change leads to dyspnea, impairs exercise capacity, contributes to respiratory failure, and affects cardiopulmonary function. Lung volume reduction surgery (LVRS) has been a traditional treatment option for severe emphysema, but it is associated with significant risks and morbidity, leading to the development of less invasive alternatives like Bronchoscopic Lung Volume Reduction (BLVR).

The objective of this article is to review the mechanisms, patient selection criteria, and diagnostic workup for BLVR and to discuss its efficacy, safety, and role in the management of COPD, particularly focusing on patients with severe emphysema. Techniques for BLVR, including endobronchial valves (EBV), coils, and bronchoscopic thermal vapor ablation (BTVA), offer a minimally invasive alternative to lung volume reduction surgery (LVRS) by targeting diseased lung regions to reduce hyperinflation and improve respiratory mechanics. Endobronchial valves work by blocking airflow to the most affected lung areas, coils provide mechanical compression to reduce lung volume, and BTVA induces a localized inflammatory response to achieve volume reduction. These interventions have shown significant improvement in lung function, exercise capacity, and quality of life in selected patients with severe emphysema, as evidenced by multiple randomized controlled trials and clinical studies.

Additionally, advancements in patient selection criteria, such as the use of high-resolution computed tomography (HRCT) to assess fissure completeness and collateral ventilation, have further enhanced the success rates of BLVR procedures.

This review aims to provide a comprehensive evaluation of current evidence and future directions for BLVR in COPD management, emphasizing its potential to improve patient outcomes and reduce the burden of disease.

Background:

A range of lung conditions, including chronic bronchitis and emphysema, fall under the category of COPD. These conditions lead to airflow obstruction that is not fully reversible. Chronic bronchitis is characterized by inflammation and mucus hypersecretion in the bronchial tubes, causing chronic cough and sputum production. Emphysema involves the destruction of alveolar walls, leading to airspace enlargement and decreased elastic recoil. Hyperinflation of the lungs can occur due to morphological changes in the lung structure of patients with COPD. This physiological change leads to dyspnea, impairs exercise capacity, contributes to respiratory failure, and affects cardiopulmonary and musculoskeletal function. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD based on the severity of airflow limitation, symptoms, and history of exacerbations. It is a significant global health burden, affecting over 480 million people worldwide and ranking as the third leading cause of death. The economic impact of this disease is substantial, encompassing direct medical costs such as hospitalizations, medications, and outpatient visits, as well as indirect costs like lost productivity and disability. Despite advancements in pharmacotherapy, many patients continue to experience significant morbidity, highlighting the need for alternative treatments.

Management of COPD typically involves pharmacologic and non-pharmacologic approaches aimed at reducing symptoms, improving quality of life, and preventing disease progression and exacerbations. Pharmacologic treatments include bronchodilators, inhaled corticosteroids, and phosphodiesterase-4 inhibitors, which help to open the airways, reduce inflammation, and manage exacerbations. Non-pharmacologic treatments include pulmonary rehabilitation, which encompasses exercise training, nutritional advice, and education, and long-term oxygen therapy for patients with chronic hypoxemia. Despite these treatments, many patients continue to experience significant symptoms and disease progression, highlighting the need for additional therapeutic options.

Achieving a reduction in hyperinflation can be accomplished through lung volume reduction surgery (LVRS) by resecting emphysematous tissue using either sternotomy or video-assisted thoracoscopic surgery (VATS). Results from the National Emphysema Treatment Trial (NETT) have shown improvement in symptoms, physiology, and mortality in a group of patients with upper-lobe predominant emphysema and low exercise capacity. However, 90-day mortality was higher in the surgical group (7.9% versus 1.3%). Subgroup analysis of patients with upper-lobe predominant disease and lower exercise capacity showed a lower risk of mortality and significant improvement in health-related quality of life and exercise capacity at two years.

In response to the limitations of conventional surgical treatments, BLVR has emerged as a minimally invasive alternative to surgical interventions like LVRS and bullectomy. Techniques for BLVR, including EBV, coils, and BTVA aim to reduce lung hyperinflation, improve lung mechanics, and enhance overall respiratory function. By targeting the most diseased lung regions, these techniques seek to achieve the benefits of LVRS with fewer risks and shorter recovery times. The development and refinement of these techniques represent a significant advancement in the management of severe emphysema, offering new hope for patients who are not candidates for traditional surgical approaches.

Over the past decade, BLVR techniques have evolved significantly with the development of new devices and procedures. Among these, EBV are one of the most extensively studied techniques and have been shown to improve forced expiratory volume in one second (FEV1), six-minute walk distance (6MWD), and quality of life as measured by the St. George’s Respiratory Questionnaire (SGRQ). The Endobronchial Valve for Emphysema Palliation Trial (VENT) was one of the pioneering randomized controlled trials assessing the efficacy of EBV in patients with severe emphysema. The study found that patients undergoing BLVR experienced marked improvements in lung function, measured by FEV1 (6.8%), as well as increased exercise capacity (6MWD by 19.1 meters). Additionally, quality of life, assessed by the SGRQ, showed significant enhancements (3.4 points) compared to the control group.

Further solidifying the benefits of BLVR, the LIBERATE trial evaluated the Zephyr endobronchial valve in a similar patient population. The results demonstrated substantial improvements in lung function, with a 17.96% increase in FEV1, as well as enhanced exercise capacity, evidenced by a 39.31-meter improvement in the 6MWD. Additionally, patients reported a significant improvement in quality of life, with a 7.05-point reduction in the SGRQ score. Importantly, the trial highlighted the necessity of careful patient selection, particularly noting that those with heterogeneous emphysema and low collateral ventilation derived the most pronounced benefit from the procedure.

Other studies, such as the EMPROVE trial, have investigated the efficacy of endobronchial coils, showing comparable improvements in lung function and patient-reported outcomes. These coils are particularly beneficial for patients with homogeneous emphysema, expanding the applicability of BLVR to a broader patient cohort. To achieve lung volume reduction, BTVA induces a localized inflammatory response, which has demonstrated significant improvements in FEV1 and quality of life. This technique works by delivering thermal energy to the targeted lung areas, causing controlled damage and subsequent fibrosis, which helps in reducing lung volume.

In addition to EBV, coils, and BTVA, other BLVR techniques have been explored. These include biological lung volume reduction, which uses a biodegradable hydrogel to induce an inflammatory response and subsequent lung volume reduction. The AeriSeal system, which utilizes a synthetic non-biological foam, operates on a similar principle to induce inflammation and shrinkage of lung tissue. Another innovative approach is airway bypass stenting, which creates extra-anatomic passages to allow trapped air to escape from hyperinflated lung regions, reducing air trapping and improving lung mechanics.

Selecting the right patients is critical for the success of BLVR procedures. Ideal candidates typically have heterogeneous emphysema with little to no collateral ventilation, which can be assessed using tools such as the Chartis system and high-resolution computed tomography (HRCT) scans. Additionally, it is important to assess the overall health and comorbid conditions of the patients to ensure they can tolerate the procedure and recovery.

Despite its promise, BLVR is associated with potential risks, including pneumothorax, exacerbations, and respiratory infections. Ongoing research aims to refine patient selection criteria, improve procedural techniques, and assess long-term outcomes to establish BLVR as a standard care option in COPD management. The evolution of BLVR techniques continues to enhance the therapeutic landscape for COPD, providing new avenues for improving patient outcomes and quality of life. Recent studies have also focused on the combination of different BLVR techniques and the development of new devices to further improve the efficacy and safety of these procedures.

Mechanisms of Action:

The primary mechanisms of action for BLVR techniques include the induction of atelectasis, restoration of lung elastic recoil, and reduction of hyperinflated lung volumes. Each approach employs a unique method to achieve these outcomes, tailored to different patient anatomies and disease characteristics.

ENDOBRONCHIAL VALVES

One of the most extensively studied techniques for BLVR is the use of EBV. These one-way valves, such as the Zephyr and Spiration valves, are placed bronchoscopically into the airways that supply the most diseased lung regions. They allow air to exit but prevent it from re-entering the targeted lobe, leading to the collapse (atelectasis) of the hyperinflated lung tissue. This reduction in lung volume decreases lung hyperinflation, improves diaphragmatic function, and enhances overall respiratory mechanics. Specific patient selection criteria for this technique include the presence of heterogeneous emphysema and low collateral ventilation, which can be assessed using HRCT and the Chartis System. Studies have shown that EBV can significantly improve FEV1, 6MWD, and quality of life as measured by the SGRQ.

COILS

Another promising BLVR technique involves the use of coils. These coils are made of nitinol, a shape-memory alloy. Coils are deployed bronchoscopically into the airways of the affected lung regions. Once in place, the coils compress the surrounding lung tissue, resulting in volume reduction and the restoration of elastic recoil. This compression re-tensions the airway walls, reducing airway collapse during expiration and improving overall lung function. Clinical studies have demonstrated improvements in FEV1, exercise capacity, and quality of life in patients treated with coils. Coils are particularly beneficial for patients with homogeneous emphysema, expanding the applicability of BLVR to a broader patient cohort.

THERMAL VAPOR ABLATION

To achieve lung volume reduction, BTVA involves the bronchoscopic delivery of heated water vapor to targeted lung areas. The thermal energy induces a localized inflammatory response, leading to fibrosis and subsequent lung volume reduction. This process reduces hyperinflation and improves lung mechanics by decreasing the volume of diseased lung tissue. The procedure involves precise targeting of diseased segments using HRCT and bronchoscopic guidance. Patients with upper-lobe predominant emphysema and little to no collateral ventilation are the best candidates. Studies have shown significant improvements in FEV1 and quality of life in patients with severe emphysema.

BIOLOGICAL LUNG VOLUME REDUCTION

Biological lung volume reduction uses a biodegradable hydrogel that is bronchoscopically delivered to the target lung regions. The hydrogel induces an inflammatory response that results in fibrosis and lung volume reduction, mimicking the effects of surgical lung volume reduction but with a less invasive approach. The hydrogel is designed to dissolve or be absorbed over time, and the resulting fibrosis helps reduce hyperinflation. This technique is still in experimental stages, and careful patient selection is required to avoid complications such as airway obstruction or excessive inflammation.

AERISEAL SYSTEM

The AeriSeal system utilizes a synthetic non-biological foam to achieve lung volume reduction. The foam is bronchoscopically delivered to the airways, where it induces an inflammatory response and tissue shrinkage, leading to a reduction in lung volume and improved respiratory mechanics. The AeriSeal foam fills the airways of the targeted lung segments, resulting in a chemical pleurodesis-like effect. This technique is particularly useful in patients with collateral ventilation where traditional endobronchial valves may be less effective.

AIRWAY BYPASS STENTING

Airway bypass stenting involves creating extra-anatomic passages to allow trapped air to escape from hyperinflated lung regions. These stents are placed bronchoscopically to facilitate the reduction of air trapping and improvement of lung mechanics. The procedure is particularly considered for patients with homogeneous emphysema and significant collateral ventilation. Stents are made of metal or other biocompatible materials and are inserted using bronchoscopic guidance.

Diagnostic Workup:

Patient selection is critical for the successful application of BLVR for treating severe emphysema in COPD patients. Identifying appropriate candidates for BLVR involves a comprehensive evaluation to determine the severity of emphysema, the extent of hyperinflation, and the suitability of lung anatomy for the procedure. This meticulous workup ensures that the benefits of BLVR are maximized while minimizing potential risks.

CLINICAL EVALUATION

The initial step in selecting patients involves a thorough clinical evaluation, which includes a detailed medical history and physical examination. Key factors to assess include the severity of symptoms, history of exacerbations, smoking status, and previous treatments. Patients who remain symptomatic despite optimal medical therapy, such as pharmacologic treatments and pulmonary rehabilitation, are considered potential candidates for BLVR. Additionally, the patient’s overall health status and the presence of comorbid conditions must be carefully considered.

PULMONARY FUNCTION TESTS

Pulmonary function tests (PFTs) are essential in assessing the degree of airflow limitation and hyperinflation. Important parameters include:

• FEV1: Typically, candidates have an FEV1 less than 45% of the predicted value.
• Total Lung Capacity (TLC) and Residual Volume (RV): High values indicate significant hyperinflation. Candidates usually have an RV greater than 150 to 175% of the predicted value.

IMAGING STUDIES

High-resolution computed tomography (HRCT) is a critical imaging modality in the workup for BLVR, providing detailed visualization of lung anatomy and emphysema distribution. HRCT helps identify:

• Emphysema Heterogeneity: BLVR is most effective in patients with heterogeneous emphysema, where there are clearly defined areas of more severely diseased lung tissue. Patients with upper-lobe predominant emphysema tend to benefit the most.
• Collateral Ventilation: The presence of collateral ventilation, which is airflow between lung segments via collateral channels, can reduce the efficacy of BLVR. Advanced imaging techniques, such as Chartis system assessments, are used to evaluate the presence of collateral ventilation. Patients with low or absent collateral ventilation are ideal candidates.

CARDIOPULMONARY EXERCISE TESTING

Cardiopulmonary exercise testing assesses exercise capacity and identifies any cardiovascular limitations to undergoing BLVR. This testing provides baseline data on the patient’s functional status and helps predict the potential improvement in exercise capacity following the procedure. Parameters such as peak oxygen uptake (VO2 max) and anaerobic threshold are measured to gauge the patient’s cardiopulmonary reserve.

ADDITIONAL ASSESSMENTS

Other specialized assessments may be conducted based on individual patient needs, including:

• Echocardiography: Used to evaluate cardiac function and exclude significant cardiac comorbidities that may contraindicate BLVR.
• Arterial Blood Gas (ABG) Analysis: Conducted to assess baseline gas exchange and detect any hypoxemia or hypercapnia.

EXCLUSION CRITERIA

Certain conditions exclude patients from being considered for BLVR. These include severe pulmonary hypertension, frequent exacerbations or recent respiratory infections, significant cardiac comorbidities, severe bullous disease, and inability to tolerate bronchoscopic procedures. Additionally, patients with homogeneous emphysema or significant collateral ventilation are generally not suitable candidates for this procedure. Patients with a low diffusing capacity of the lung for carbon monoxide (DLCO) are also often excluded due to higher risk of adverse outcomes.

MULTIDISCIPLINARY TEAM APPROACH

A multidisciplinary team approach is essential in the selection process, involving pulmonologists, radiologists, thoracic surgeons, and respiratory therapists. This team collaborates to review all diagnostic information and develop a comprehensive treatment plan tailored to the individual patient’s needs. The involvement of a multidisciplinary team ensures a thorough evaluation and optimizes patient outcomes by leveraging the expertise of various specialists.

PATIENT EDUCATION AND INFORMED CONSENT

Educating patients about the potential risks and benefits of BLVR is crucial for ensuring informed consent. Patients should be made aware of the possible complications, as well as the expected improvements in lung function and quality of life. Providing comprehensive education helps patients set realistic expectations and fosters better cooperation during the treatment process.

Efficacy of Bronchoscopic Lung Volume Reduction:

The effectiveness of BLVR has been substantiated through several key clinical trials. This section provides a detailed analysis based on current evidence from clinical studies, including significant trials such as VENT, LIBERATE, and EMPROVE, as well as systematic reviews.

ENDOBRONCHIAL VALVES

Significant improvements in lung function, exercise capacity, and quality of life have been demonstrated in patients treated with endobronchial valves. Key findings include:

• Lung Function: Studies have shown an increase in FEV1 by approximately 15-20% post-procedure.
• Exercise Capacity: Patients treated with EBV have shown improvements in the 6MWD by an average of 30-50 meters. The VENT study also reported increased exercise capacity, gauged through the 6MWD.
• Quality of life: Improvements in the SGRQ scores, reflecting better overall health status and reduced symptoms. The LIBERATE trial further solidified these findings, showing substantial improvements in both lung function and quality of life metrics.

COILS

Clinical studies have reported the following outcomes for coil treatments:

• Lung Function: Significant improvements in FEV1 by 10-15%. The EMPROVE trial demonstrated that coil treatment led to notable improvements in FEV1 and exercise capacity.
• Exercise Capacity: An increase in the 6MWD by 20-40 meters.
• Quality of Life: Positive changes in SGRQ scores, indicating enhanced patient-reported outcomes. Coils are particularly beneficial for patients with homogeneous emphysema, expanding the applicability of BLVR to a broader patient cohort.

THERMAL VAPOR ABLATION

Promising results have been shown in clinical trials using BTVA, with improvements in several key areas:

• Lung Function: Increases in FEV1 by approximately 12-18%.
• Quality of Life: Significant improvements in SGRQ scores, indicating better symptom management and overall health.

OTHER TECHNIQUES

Emerging techniques such as biological lung volume reduction and the AeriSeal system have also demonstrated efficacy in early studies. These techniques aim to induce lung volume reduction through different mechanisms, providing additional options for patient-specific treatment. While the overall efficacy of BLVR is well-documented, the degree of benefit varies based on individual patient characteristics and the specific technique employed. Patients with more localized, heterogeneous emphysema and minimal collateral ventilation tend to experience the greatest improvements. Conversely, those with homogeneous emphysema may still benefit but to a lesser extent.

Safety of Bronchoscopic Lung Volume Reduction:

While BLVR offers a less invasive alternative to LVRS, it is not without risks. Common complications include pneumothorax, exacerbations, and respiratory infections, each presenting significant challenges in the post-procedural management of patients.

PNEUMOTHORAX

Pneumothorax, a condition where air leaks into the space between the lung and chest wall, is one of the most frequent and serious complications of BLVR. This complication typically occurs within the first 72 hours after the procedure and may require interventions such as chest tube placement or, in severe cases, surgery. The incidence of pneumothorax varies depending on the technique used and the patient’s lung condition, emphasizing the need for close monitoring during the early post-operative period. The LIBERATE study reported a 26.6% incidence of pneumothorax in the treatment group within the first 45 days post-procedure, which underscores the importance of vigilant monitoring and prompt management.

EXACERBATIONS

Another common complication following BLVR is exacerbations, or acute worsening of symptoms associated with COPD. These exacerbations can be triggered by the procedure itself or by subsequent respiratory infections. Hospitalization and intensive medical management, including the use of antibiotics, corticosteroids, and bronchodilators, may be necessary. The risk of exacerbations underscores the importance of optimizing the patient’s medical condition before the procedure and providing vigilant post-procedural care. The VENT trial noted increased rates of COPD exacerbations requiring hospitalization in the BLVR group compared to the control group.

RESPIRATORY INFECTIONS

Respiratory infections, including pneumonia and bronchitis, are also observed in patients undergoing BLVR. The introduction of devices into the airways can potentially introduce pathogens or disrupt the normal mucociliary clearance, leading to infections. Prophylactic antibiotics and strict aseptic techniques during the procedure can help mitigate this risk, but infections remain a significant concern. The EMPROVE trial highlighted the occurrence of respiratory infections post-procedure, emphasizing the need for preventive measures and early treatment.

HEMOPTYSIS

Hemoptysis, or coughing up blood, can range from mild to severe and is another potential complication of BLVR. This complication requires prompt identification and management to prevent further morbidity. Device-related issues such as migration or malfunction of the valves or coils also pose significant risks. For instance, the EMPROVE trial reported a higher incidence of thoracic serious adverse events, including hemoptysis and device-related complications.

The incidence of these complications highlights the critical importance of careful patient selection and thorough pre-procedural evaluation. Patients with significant comorbidities, frequent exacerbations, or severe bullous disease may face higher risks and may not be ideal candidates for BLVR.

LUNG TRANSPLANTATION CONSIDERATIONS

Lung transplantation offers the most definitive treatment for end-stage COPD, providing substantial improvements in lung function and quality of life. However, this option is limited by the availability of donor organs, the need for lifelong immunosuppression, and the risk of complications such as rejection and infections. The eligibility criteria for lung transplantation are stringent, and the procedure is generally reserved for patients with the most severe disease who have exhausted all other treatment options. Patients who have undergone valve treatment may still be eligible for lung transplantation if their condition deteriorates further or if complications arise.

Advantages of BLVR

• Minimally Invasive: Procedures for BLVR procedures are minimally invasive compared to LVRS, reducing the risks associated with open surgery and offering shorter recovery times.
• Suitability for High-Risk Patients: It is often suitable for patients who are not candidates for LVRS or transplantation due to comorbidities or overall health status.
• Targeted Treatment: This approach allows for precise targeting of the most affected lung regions, maximizing the therapeutic benefit while minimizing the impact on healthier lung tissue.

KEY CLINICAL TRIALS

• The VENT trial demonstrated that endobronchial valves significantly improved lung function, exercise capacity, and quality of life compared to standard medical therapy.
• The LIBERATE trial further confirmed the efficacy of Zephyr endobronchial valves, showing substantial improvements in FEV1, exercise capacity, and quality of life, especially in patients with heterogeneous emphysema and low collateral ventilation.
• The EMPROVE trial evaluated endobronchial coils and showed comparable improvements in lung function and patient-reported outcomes, highlighting the benefits of coils for patients with homogeneous emphysema.

LIMITATIONS OF BRONCHOSCOPIC LUNG VOLUME REDUCTION

• Complications: Procedures involving BLVR are associated with risks such as pneumothorax and exacerbations. These complications necessitate careful patient selection and thorough pre-procedural evaluation.
• Patient Selection: The success of BLVR heavily relies on appropriate patient selection. Patients with significant comorbidities or severe bullous disease may not be ideal candidates.

Future Directions

The field of BLVR is rapidly evolving, with ongoing research and advancements aimed at enhancing its efficacy, safety, and applicability. Future directions for BLVR involve the development of new techniques, improving patient selection criteria, optimizing procedural methods, and exploring combination therapies.

One key area of future research is the development and refinement of new BLVR devices and techniques. Innovations in EBV, coils, and BTVA are continually being explored to enhance their effectiveness and reduce associated risks. These advancements could lead to more efficient reduction of lung hyperinflation and improved patient outcomes. Additionally, combining different BLVR techniques might provide synergistic benefits, offering more comprehensive treatment options for patients with varying patterns of emphysema.

Accurate patient selection is crucial for the success of BLVR. Future research is focused on refining patient selection criteria to identify the patients who will benefit the most from BLVR. Advances in imaging technology, such as HRCT and functional imaging like V/Q scans, are essential in assessing emphysema heterogeneity and collateral ventilation more accurately. Improved biomarkers and predictive models could also play a significant role in personalizing treatment plans and predicting patient responses to BLVR.

Optimizing procedural techniques is another key area of focus. Researchers are investigating the best practices for device placement and procedural protocols to minimize complications and enhance outcomes. Studies are also examining the role of anesthesia and sedation protocols in improving patient comfort and procedural success. The goal is to develop standardized protocols that can be widely adopted to ensure consistent and optimal results across different clinical settings.

Long-term outcomes and the durability of BLVR benefits are areas requiring further investigation. While current studies have demonstrated short- to medium-term improvements, the sustainability of these benefits over several years remains to be fully understood. Longitudinal studies and registries tracking patient outcomes over extended periods will provide valuable insights into the longevity of BLVR’s effects and help identify factors that influence long-term success.

Combining BLVR with other treatments is a promising strategy to maximize therapeutic benefits. For instance, integrating pulmonary rehabilitation with BLVR can enhance overall patient outcomes by improving physical fitness and respiratory function. Research is also exploring the potential of combining different BLVR techniques, such as using both EBV and coils, to achieve greater lung volume reduction and improve respiratory mechanics. Additionally, combining BLVR with pharmacotherapy and lifestyle interventions could further enhance treatment efficacy.

The integration of technological advances, such as artificial intelligence (AI) and machine learning, holds potential for enhancing BLVR. These technologies can be used to analyze large datasets and identify patterns that predict patient outcomes, helping to refine patient selection and personalize treatment plans. AI-driven tools can also assist in the interpretation of imaging studies, providing more precise assessments of lung anatomy and function.

Furthermore, recent editorial insights highlight the evolving nature of BLVR. According to Martínez Tomás et al., the future challenges in this field will involve determining the appropriate timing for referrals, improving methods for selecting the lobe to be treated, correctly defining cut-off points for fissure integrity, and investigating methods to repair incomplete fissures. These efforts aim to broaden the applicability of BLVR to a larger patient population, especially those with collateral ventilation.

An emerging approach under investigation is the combination of surgical fissure completion with subsequent BLVR using EBV. This technique addresses the issue of collateral ventilation in patients with incomplete interlobar fissures. Studies have shown promising results with robotic-assisted thoracic surgery (RATS) to complete the fissures, followed by EBV placement. This combined procedure could potentially expand the pool of patients eligible for BLVR by improving the isolation of target lobes and enhancing the efficacy of valve placement. However, the approach is not yet ready for widespread clinical use. As highlighted by Majid et al., the outcomes are variable and the procedure carries risks, necessitating that it be performed within the context of controlled clinical trials. The COMPLETE-1 and SAVED-1 trials are currently evaluating the efficacy and safety of this combined approach.

Conclusion

A promising and less invasive alternative to traditional surgical interventions for managing severe emphysema in patients with COPD is BLVR. Techniques such as EBV, coils, and BTVA have demonstrated significant improvements in lung function, exercise capacity, and quality of life. Key trials like VENT, LIBERATE, and EMPROVE provide robust evidence supporting these benefits, especially in carefully selected patient populations. However, complications such as pneumothorax, exacerbations, and respiratory infections necessitate careful patient selection and thorough management.

Comparing BLVR with other treatment modalities—such as conventional medical therapy, pulmonary rehabilitation, LVRS, and lung transplantation—highlights its unique benefits. Medical therapy and pulmonary rehabilitation provide symptomatic relief; however, they do not address the underlying issues of hyperinflation and reduced lung elasticity seen in emphysema. While LVRS and lung transplantation offer significant functional improvements, these options are limited by their invasiveness and associated risks. In contrast, BLVR offers a minimally invasive approach suitable for a broader range of patients, including those with comorbidities who are not candidates for more invasive procedures.

Future directions for BLVR are promising and include the development of new devices and techniques, improved patient selection criteria, optimized procedural methods, and exploration of combination therapies. Long-term studies are essential to understand the durability of BLVR benefits and to identify factors influencing long-term success. Integrating BLVR with other therapeutic modalities and leveraging technological advances such as artificial intelligence will further enhance its efficacy and safety. In conclusion, BLVR represents a significant advancement in the management of severe emphysema, offering new hope for patients and advancing the therapeutic landscape for COPD.

References

1. Boers, E., Barrett, M., Su, J. G., Benjafield, A. V., Sinha, S., Kaye, L., … & Malhotra, A. (2023). Global burden of chronic obstructive pulmonary disease through 2050. JAMA Network Open, 6(12), e2346598-e2346598.
2. Liu, Y. (2023). Trends in the prevalence of chronic obstructive pulmonary disease among adults aged≥ 18 years—United States, 2011–2021. MMWR. Morbidity and Mortality Weekly Report, 72.
3. Celli, B. R., Singh, D., Vogelmeier, C., & Agusti, A. (2022). New perspectives on chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 2127-2136.
4. Agusti, A., Ambrosino, N., Blackstock, F., Bourbeau, J., Casaburi, R., Celli, B., … & ZuWallack, R. (2023). COPD: providing the right treatment for the right patient at the right time. Respiratory Medicine, 207, 107041.
5. Alshabani, K., Gildea, T. R., Machuzak, M., Cicenia, J., & Hatipoğlu, U. (2020). Bronchoscopic lung volume reduction with valves: What should the internist know?. Cleveland Clinic Journal of Medicine, 87(5), 278-287.
6. Rossi, A., Aisanov, Z., Avdeev, S., Di Maria, G., Donner, C. F., Izquierdo, J. L., … & Miravitlles, M. (2015). Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respiratory medicine, 109(7), 785-802.
7. Criner, G. J., Scharf, S. M., Falk, J. A., Gaughan, J. P., Sternberg, A. L., Patel, N. B., … & National Emphysema Treatment Trial Research Group*. (2007). Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. American journal of respiratory and critical care medicine, 176(3), 253-260.
8. Sciurba, F. C., Ernst, A., Herth, F. J., Strange, C., Criner, G. J., Marquette, C. H., … & McLennan, G. (2010). A randomized study of endobronchial valves for advanced emphysema. New England Journal of Medicine, 363(13), 1233-1244.
9. Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., … & Slebos, D. J. (2018). A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). American journal of respiratory and critical care medicine, 198(9), 1151-1164.
10. Criner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., … & Martel, S. (2019). Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial. American journal of respiratory and critical care medicine, 200(11), 1354-1362.
11. Fishman A., Martinez F., Naunheim K., Piantadosi S., Wise R., Ries A., et. al.: A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: pp. 2059-2073.
12. Marchetti, N., Duffy, S., & Criner, G. J. (2020). Interventional bronchoscopic therapies for chronic obstructive pulmonary disease. Clinics in Chest Medicine, 41(3), 547-557.
13. Xu, W., Wang, J., He, X., Wang, J., Wu, D., & Li, G. (2020). Bronchoscopic lung volume reduction procedures for emphysema: Q network meta-analysis. Medicine, 99(5), e18936.
14. Zhi, L., Liao, L., Wu, Z., Wang, T., Ye, Y., Li, H., … & Zhang, L. (2023). Impact of bronchoscopic thermal vapor ablation on lung volume reduction in patients with emphysema: a meta-analysis. BMC Pulmonary Medicine, 23(1), 405.
15. Koster, T. D., Eberhardt, R., Huebner, R. H., Valipour, A., Herth, F., Klooster, K., … & Slebos, D. J. (2022). A multicenter, prospective, single-arm clinical investigation of a modified staged treatment algorithm using the AeriSeal system-The STAGE trial. Respiratory Medicine, 203, 106989.
16. Shah, P. L., Slebos, D. J., Cardoso, P. F. G., Cetti, E., Voelker, K., Levine, B., … & Sybrecht, G. W. (2011). Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial. The Lancet, 378(9795), 997-1005.
17. Magge, A., Kent, M. S., Ospina-Delgado, D., Swenson, K. E., Parikh, M. S., Zhang, C., … & Majid, A. (2022). Robotic-assisted Fissure Completion for Lung Volume Reduction with Endobronchial Valves. Annals of the American Thoracic Society, 19(12), 2087-2090.
18. Majid, A., Rosenberg, B. J., Delgado, D. O., & Gangadharan, S. (2023). Bronchoscopic Lung Volume Reduction After Surgical Fissure Completion Is Not Ready for Prime Time. Chest, 163(1), e48-e49.
19. Dumanli, A., Metin, B., & Gunay, E. (2020). Endobronchial valve vs coil for lung volume reduction in emphysema: results from a tertiary care centre in Turkey. Annals of Saudi Medicine, 40(6), 469-476.
20. Joglekar, M. M., Slebos, D. J., Leijten, J., Burgess, J. K., & Pouwels, S. D. (2021). Crosslink bio-adhesives for bronchoscopic lung volume reduction: current status and future direction. European Respiratory Review, 30(162).
21. Tomás, R. M., Gómez, A. B., & Viedma, E. C. (2023). Bronchoscopy Valves for Lung Volume Reduction: Present and Future. Archivos de bronconeumología: Organo oficial de la Sociedad Española de Neumología y Cirugía Torácica SEPAR y la Asociación Latinoamericana de Tórax (ALAT), 59(11), 707-708.
22. Gordon, M., Duffy, S., & Criner, G. J. (2018). Lung volume reduction surgery or bronchoscopic lung volume reduction: is there an algorithm for allocation?. Journal of thoracic disease, 10(Suppl 23), S2816.
23. BIDMC/MGH Interventional Pulmonary Fellowship. Ongoing Trials. Available at: https://www.bidmcmghipfellowship.com/ongoing-trials.html.